Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 5/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11983571 | 0.83 | CCR1 (0.55) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL31375150 | 0.81 | CCNC (0.58) | AXLACVR1BTGFBR1PIM1PIM3 | |
| SCHEMBL24316789 | 0.80 | FYN (0.54) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL16561177 | 0.80 | MKNK1 (0.51) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL23119645 | 0.80 | FGFR3 (0.58) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL29539345 | 0.80 | FYN (0.54) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL29538959 | 0.80 | CSF1R (0.47) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL21408152 | 0.80 | CSF1R (0.47) | ACVR1BTGFBR1PIM1PIM3PIM2 | |
| SCHEMBL16561327 | 0.78 | CCR1 (0.58) | ACVR1BTGFBR1PIM1LRRK2FGFR3 | |
| SCHEMBL24783964 | 0.78 | MAPT (0.48) | ACVR1BTGFBR1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-03-18 | — | — | US | disclosed |
| CN-108779115-B | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078975-A1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | CRHR2, CRHR1, CRH | AXL 3240/4885ACVR1B 1878/4885TGFBR1 2030/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | AXL 3240/4885ACVR1B 1878/4885TGFBR1 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.